{
  "zip": "V6C 1G8",
  "sector": "Healthcare",
  "longBusinessSummary": "Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of nonÂalcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. The company's lead candidate is NP-120, a N-methyl-D-aspartate (NMDA) receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.",
  "city": "Vancouver",
  "phone": "604 646 1553",
  "state": "BC",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://algernonpharmaceuticals.com",
  "maxAge": 1,
  "address1": "700 West Pender Street",
  "industry": "Biotechnology",
  "address2": "Suite 915",
  "previousClose": 0.1894,
  "regularMarketOpen": 0.19,
  "twoHundredDayAverage": 0.22768043,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 0.2,
  "navPrice": null,
  "averageDailyVolume10Day": 492669,
  "totalAssets": null,
  "regularMarketPreviousClose": 0.1894,
  "fiftyDayAverage": 0.23319882,
  "trailingAnnualDividendRate": null,
  "open": 0.19,
  "averageVolume10days": 492669,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": -0.029487,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 0.18,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 326353,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 25062678,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 894843,
  "priceToSalesTrailing12Months": null,
  "dayLow": 0.18,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 326353,
  "fiftyTwoWeekHigh": 0.4867,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.044,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 0.2,
  "exchange": "PNK",
  "shortName": "ALGERNON PHARMACEUTICALS INC",
  "longName": "Algernon Pharmaceuticals Inc.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "AGNPF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_327047624",
  "uuid": "9e635ff8-2acb-39f5-ab61-be8834cb948f",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 138338000,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1598832000,
  "heldPercentInstitutions": 0.06722,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.063200004,
  "nextFiscalYearEnd": 1661904000,
  "mostRecentQuarter": 1598832000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 132676721,
  "enterpriseValue": 27006460,
  "threeYearAverageReturn": null,
  "lastSplitDate": 1539734400,
  "lastSplitFactor": "1:2",
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.19,
  "logo_url": "https://logo.clearbit.com/algernonpharmaceuticals.com"
}